We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.
- Authors
Brown, Cortlyn; Noble, Jeanne; Coralic, Zlatan
- Abstract
As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.2 We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.
- Subjects
HOSPITAL emergency services; INVESTIGATIONAL drugs; COVID-19
- Publication
Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 2020, Vol 21, Issue 3, p510
- ISSN
1936-900X
- Publication type
Article
- DOI
10.5811/westjem.2020.3.47328